• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺动脉高压的诊断延迟:来自澳大利亚和新西兰肺动脉高压注册中心的见解。

Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry.

机构信息

Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Respiratory Department, Sunshine Coast University Hospital, Sunshine Coast Region, QLD, Australia.

出版信息

Respirology. 2020 Aug;25(8):863-871. doi: 10.1111/resp.13768. Epub 2020 Jan 30.

DOI:10.1111/resp.13768
PMID:31997504
Abstract

BACKGROUND AND OBJECTIVE

Early diagnosis of PAH is clinically challenging. Patterns of diagnostic delay in Australian and New Zealand PAH populations have not been explored in large-scale studies. We aimed to evaluate the magnitude, risk factors and survival impact of diagnostic delay in Australian and New Zealand PAH patients.

METHODS

A cohort study of PAH patients from the PHSANZ Registry diagnosed from 2004 to 2017 was performed. Diagnostic interval was the time from symptom onset to diagnostic right heart catheterization as recorded in the registry. Factors associated with diagnostic delay were analysed in a multivariate logistic regression model. Survival rates were compared across patients based on the time to diagnosis using Kaplan-Meier method and Cox regression.

RESULTS

A total of 2044 patients were included in analysis. At diagnosis, median age was 58 years (IQR: 43-69), female-to-male ratio was 2.8:1 and majority of patients were in NYHA FC III-IV (82%). Median diagnostic interval was 1.2 years (IQR: 0.6-2.7). Age, CHD-PAH, obstructive sleep apnoea and peripheral vascular disease were independently associated with diagnostic interval of ≥1 year. No improvement in diagnostic interval was seen during the study period. Longer diagnostic interval was associated with decreased 5-year survival.

CONCLUSION

PAH patients experience significant diagnostic interval, which has not improved despite increased community awareness. Age, cardiovascular and respiratory comorbidities are significantly associated with longer time to diagnosis. Mortality rates appear higher in patients who experience longer diagnostic interval.

摘要

背景和目的

肺动脉高压(PAH)的早期诊断具有临床挑战性。在大规模研究中,尚未探讨澳大利亚和新西兰 PAH 人群的诊断延迟模式。我们旨在评估澳大利亚和新西兰 PAH 患者诊断延迟的程度、危险因素和对生存的影响。

方法

对 2004 年至 2017 年期间 PHSANZ 登记处诊断的 PAH 患者进行了队列研究。诊断间隔是从症状发作到登记处记录的诊断右心导管检查的时间。使用多元逻辑回归模型分析与诊断延迟相关的因素。使用 Kaplan-Meier 方法和 Cox 回归比较基于诊断时间的患者生存率。

结果

共纳入 2044 例患者进行分析。在诊断时,中位年龄为 58 岁(IQR:43-69),男女比例为 2.8:1,大多数患者处于纽约心脏协会功能分级(NYHA)III-IV 级(82%)。中位诊断间隔为 1.2 年(IQR:0.6-2.7)。年龄、先心病相关 PAH、阻塞性睡眠呼吸暂停和外周血管疾病与诊断间隔≥1 年独立相关。在研究期间,诊断间隔没有改善。诊断间隔较长与 5 年生存率降低相关。

结论

PAH 患者经历了显著的诊断间隔,尽管社区意识增强,但间隔时间并未改善。年龄、心血管和呼吸系统合并症与诊断时间延长显著相关。在经历较长诊断间隔的患者中,死亡率似乎更高。

相似文献

1
Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry.肺动脉高压的诊断延迟:来自澳大利亚和新西兰肺动脉高压注册中心的见解。
Respirology. 2020 Aug;25(8):863-871. doi: 10.1111/resp.13768. Epub 2020 Jan 30.
2
Characteristics, Long-term Survival, and Risk Assessment of Pediatric Pulmonary Arterial Hypertension in China: Insights From a National Multicenter Prospective Registry.中国儿科肺动脉高压的特征、长期生存及风险评估:来自全国多中心前瞻性注册研究的见解。
Chest. 2023 Jun;163(6):1531-1542. doi: 10.1016/j.chest.2022.11.038. Epub 2022 Dec 5.
3
The COngenital HeARt Disease in adult and Pulmonary Hypertension (COHARD-PH) registry: a descriptive study from single-center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia.成人先天性心脏病和肺动脉高压(COHARD-PH)登记研究:印度尼西亚单中心成人先天性心脏病和肺动脉高压医院登记处的描述性研究。
BMC Cardiovasc Disord. 2020 Apr 7;20(1):163. doi: 10.1186/s12872-020-01434-z.
4
Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges.澳大利亚肺动脉高压的药物治疗:现状与挑战。
Heart Lung Circ. 2020 Oct;29(10):1459-1468. doi: 10.1016/j.hlc.2020.01.017. Epub 2020 Mar 6.
5
Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study.红斑狼疮性肺动脉高压在系统性红斑狼疮患者中的发病率和生存影响:一项全国性队列研究。
Arthritis Res Ther. 2019 Mar 27;21(1):82. doi: 10.1186/s13075-019-1868-0.
6
Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort.REVEAL 2.0 风险评分的澳大利亚和新西兰肺动脉高压登记队列回顾性验证。
Chest. 2020 Jan;157(1):162-172. doi: 10.1016/j.chest.2019.08.2203. Epub 2019 Sep 26.
7
[Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].[先天性心脏病相关肺动脉高压患者不同亚型的死亡危险因素及临床特征]
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Apr 24;48(4):315-322. doi: 10.3760/cma.j.cn112148-20190628-00364.
8
Investigating the "sex paradox" in pulmonary arterial hypertension: Results from the Pulmonary Hypertension Association Registry (PHAR).研究肺动脉高压中的“性别悖论”:来自肺动脉高压协会注册中心(PHAR)的结果。
J Heart Lung Transplant. 2024 Jun;43(6):901-910. doi: 10.1016/j.healun.2024.02.004. Epub 2024 Feb 13.
9
Pulmonary hypertension in Saudi Arabia: First data from the SAUDIPH registry with a focus on pulmonary arterial hypertension.沙特阿拉伯的肺动脉高压:来自 SAUDIPH 注册中心的首批数据,重点关注肺动脉高压。
Respirology. 2021 Jan;26(1):92-101. doi: 10.1111/resp.13879. Epub 2020 Jun 15.
10
Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.在 REVEAL 注册研究中肺动脉高压患者的功能分级改善与 3 年生存结局。
Chest. 2013 Jul;144(1):160-168. doi: 10.1378/chest.12-2417.

引用本文的文献

1
Sex differences in pulmonary (arterial) hypertension: does it matter?肺动脉高压中的性别差异:这重要吗?
Curr Opin Pulm Med. 2025 Sep 1;31(5):411-428. doi: 10.1097/MCP.0000000000001197. Epub 2025 Jul 23.
2
Important Differences in Disease Severity, Echocardiography Findings, and Referral Delays in Non-Hispanic Black Patients With Pulmonary Arterial Hypertension.非西班牙裔黑人肺动脉高压患者在疾病严重程度、超声心动图检查结果及转诊延迟方面的重要差异
Pulm Circ. 2025 Jul 28;15(3):e70138. doi: 10.1002/pul2.70138. eCollection 2025 Jul.
3
Gaps in access to pulmonary hypertension care and opportunities for improvement: a multi-site qualitative study.
肺动脉高压护理的可及性差距与改善机会:一项多中心定性研究
BMC Pulm Med. 2025 Jul 28;25(1):355. doi: 10.1186/s12890-025-03817-4.
4
Bioinformatics Analysis Identifies a Potential Key Gene in the Pathogenesis of Pulmonary Hypertension-HSPH1.生物信息学分析确定了肺动脉高压发病机制中的一个潜在关键基因——HSPH1。
Pulm Circ. 2025 Jul 16;15(3):e70127. doi: 10.1002/pul2.70127. eCollection 2025 Jul.
5
Nobiletin alleviates hypoxia-induced pulmonary hypertension by inhibiting calcium-sensing receptor.橙皮素通过抑制钙敏感受体减轻缺氧诱导的肺动脉高压。
J Nat Med. 2025 Jun 29. doi: 10.1007/s11418-025-01921-7.
6
Treatment of pulmonary hypertension after seven world symposia.七次世界研讨会后肺动脉高压的治疗
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251342898. doi: 10.1177/17534666251342898. Epub 2025 May 23.
7
Diagnostic MicroRNA Signatures to Support Classification of Pulmonary Hypertension.支持肺动脉高压分类的诊断性微小RNA特征
Circ Genom Precis Med. 2025 Jun;18(3):e004862. doi: 10.1161/CIRCGEN.124.004862. Epub 2025 Apr 18.
8
Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries.与肺动脉高压亚组相关的社会成本:一项利用国家关联登记处的研究。
Pulm Circ. 2025 Apr 17;15(2):e70074. doi: 10.1002/pul2.70074. eCollection 2025 Apr.
9
Development and validation of multimodal deep learning algorithms for detecting pulmonary hypertension.用于检测肺动脉高压的多模态深度学习算法的开发与验证
NPJ Digit Med. 2025 Apr 10;8(1):198. doi: 10.1038/s41746-025-01593-3.
10
Pulmonary vascular dysfunction in systemic sclerosis.系统性硬化症中的肺血管功能障碍
JHLT Open. 2023 Nov 19;3:100024. doi: 10.1016/j.jhlto.2023.100024. eCollection 2024 Feb.